asTORi treatment increased the amount of 4EBP1 binding to eIF4E and concomitantly decreased the eIF4G association. The empty vector control cells behaved similarly to the parental VAL cells in that MLN0128 treatment did not affect eIF4F formation, correlating with absence of 4EBP1. In the asTORi-sensitive OCI-LY7 cells where MLN0128 basally affects formation of the eIF4F complex, MCE Company 1311982-88-3 expression of 4EBP1 did not have any apparent effects. Next we wanted to test whether asTORi treatment in 4EBP1 add-back VAL cells decreased cap dependent translation. Indeed, as measured by dual luciferase reporter assays, the 4EBP1 addback VAL cells showed a 30% decrease in cap dependent translation upon treatment with MLN0128 when compared to the untreated controls. This decrease was similar in magnitude to the effect seen in OCI-LY1 control cells. The VAL cells expressing empty vector and VAL cells with the 4EBP1 construct but without doxycycline induction behaved similarly to the parental VAL cells with no decrease in cap dependent translation following MLN0128 treatment. As 1239358-86-1 observed in the cap-binding assay, overexpression of 4EBP1 in OCI-LY7 did not alter the sensitivity to MLN0128. Lastly we assessed whether induced 4EBP1 expression in VAL cells potentiated a cell death response to MLN0128 treatment. Using propidium iodide staining to measure the percentage of cells in sub-G1 phase, we observed 30% death following MLN0128 treatment of 4EBP1 add-back VAL cells compared to the various controls. Annexin V and PI staining was used to confirm these results where VAL cells with 4EBP1 expression showed a 2- fold increase in Annexin V positive population when treated with MLN0128. We observed a similar increase in sensitivity when the cells were treated with a structurally distinct asTORi, AZD8055, indicating that these results are specific to mTOR inhibition. In summary, add-back experiments supported the conclusion that absence of 4EBP1 is one of the contributing mechanisms of asTORi resistance in VAL cells. In this study we have identified a human DLBCL line whose resistance to asTORi can be attributed in part to a low ratio of 4EBP/eIF4E expression. VAL cells lack
